^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    BluePrint

    Company:
    Agendia
    Type:
    CE Marked
    Related tests:
    29d
    Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer (Agendia Press Release)
    "Agendia®, Inc...today announced new data to be presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29 – June 2 in Chicago. The company will present two posters highlighting how MammaPrint® (MP) + BluePrint® (BP) provide biological insights into treatment response and help further refine therapeutic decision-making for patients with early-stage breast cancer (EBC)."
    Clinical data
    |
    MammaPrint® • BluePrint
    1m
    Whole transcriptome analysis reveals MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancer. (PubMed, Breast Cancer Res Treat)
    This study lays the groundwork for exploring mechanisms of LN metastasis in EBC and their relation to MammaPrint High Risk and Luminal B subtypes. These data support previous studies' association of LN metastasis with EMT and immune dysregulation.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • CD4 (CD4 Molecule)
    |
    MammaPrint® • BluePrint
    2ms
    Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Legacy Health System | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MammaPrint® • BluePrint
    2ms
    Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, The Methodist Hospital Research Institute | N=39 --> 51 | Trial completion date: Dec 2025 --> Dec 2028
    Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification • PD-L1 negative
    |
    BluePrint
    |
    Herceptin (trastuzumab) • Imfinzi (durvalumab) • Perjeta (pertuzumab)
    3ms
    Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Legacy Health System
    New P2 trial
    |
    MammaPrint® • BluePrint
    3ms
    Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B). (PubMed, Breast Cancer)
    Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    MammaPrint® • BluePrint
    6ms
    Accuracy in predicting 135° neck-shaft angle short-stem and glenoid components size in reverse shoulder arthroplasty with 3D preoperative planning. (PubMed, Musculoskelet Surg)
    3D preoperative planning demonstrated moderate to high accuracy for glenoid component selection but lower concordance for humeral stem size. Intraoperative adjustments were mainly related to metaphyseal bone quality and soft tissue tension. Future improvements in planning software should incorporate bone mineral density and humeral osteotomy variability to enhance predictive accuracy.
    Journal
    |
    BluePrint
    8ms
    Electro-Stimulated Dual-Species Catalysis Enables CO2 Fixation Toward Selective 1,4-Butanedioic Acid Biosynthesis. (PubMed, ChemSusChem)
    Thermodynamic and electrochemical evaluation indicated greater stability and electron flow in co-culture reactors (R9:ΔG = -42.29 kJ) compared to monocultures. Collectively, this study presents a scalable hybrid bioelectrochemical strategy leveraging species-specific metabolic roles and electron-steering to facilitate high-yield, selective SA production, offering a promising blueprint for sustainable carbon-based biomanufacturing.
    Journal
    |
    BluePrint
    9ms
    Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy. (PubMed, Br J Cancer)
    MMP, particularly its selected Mueller matrix elements, combined with clinical biomarkers show promise in distinguishing LBCS as validated against BluePrint®. By detecting subtle differences in tissue morphology, this approach may enhance breast cancer prognosis and help guide treatment decisions.
    Journal
    |
    BluePrint
    9ms
    BLUEMR: Blueprint® Mixed Reality Pilot Study (clinicaltrials.gov)
    P=N/A, N=44, Completed, Stryker Trauma and Extremities | Recruiting --> Completed
    Trial completion
    |
    BluePrint
    11ms
    De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trial. (PubMed, EClinicalMedicine)
    Our results provide critical references for the efficacy and biomarkers of de-escalated neoadjuvant therapy in HER2-positive breast cancer. National Natural Science Foundation of China and Natural Science Foundation of Jiangsu Province.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • EGFR positive
    |
    MammaPrint® • BluePrint
    |
    Herceptin (trastuzumab) • Irene (pyrotinib) • albumin-bound paclitaxel
    1year
    Agendia to reveal novel breast cancer outcome data identifying genomic risk and treatment disparities among diverse patient population at 2025 ASCO annual meeting (Agendia Press Release)
    "Agendia®, Inc...today announced the presentation of four major abstracts in collaboration with independent investigators at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29th– June 3rd, 2025, in Chicago, Illinois. "
    Clinical data
    |
    MammaPrint® • BluePrint